Neurogene Inc. (NGNE)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $21.56
- As of
Kresmion compiles this page from NGNE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Neurogene Inc. (NGNE): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.
See the full NGNE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NGNE on one page. Preview it with sample data, then open it live with a free account.
Preview the NGNE dossierActive signals for NGNE
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 5.4%, EPS $-1.53 vs $-1.4518 estimate
- highCONSENSUS_SELL
4 tracked funds reduced NGNE this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 60% of NGNE (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +511% to NGNE (2026Q2)
- highCONSENSUS_SELL
3 tracked funds reduced NGNE this 2026Q2, institutional consensus
FREE, NO ACCOUNT
Every signal on NGNE, as it fires
You are seeing 5 of 15 signals recorded on NGNE since 2026-05-26.
The five above landed across 2 days. The other 10 were recorded on 3 other days. 8 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NGNE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 64135M105 · 2026Q2 | $12.9M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 64135M105 · 2026Q2 | $4.5M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 64135M105 · 2026Q2 | $1.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 64135M105 · 2026Q2 | $642K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 64135M105 · 2026Q2 | $308K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NGNE
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NGNE against its peers
NGNE's return on equity of -34.1% ranks in the 66th percentile of 21 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | NGNE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 7.3M USD | 14 | 17 |
| Operating margin | n/a | -472.0% | n/a | 14 |
| Net margin | n/a | -310.8% | n/a | 14 |
| Return on equity | -34.1% | -47.0% | 66 | 21 |
| 1 year | -31.8% | -7.8% | 16 | 15 |
Peers (22): MPLT, ARVN, OCS, ALT, OVID, MNPR, RGNX, ASMB, ALLO, EPRX, PBYI, RZLT, AUTL, CBIO, CAPR, TECX, ENTX, SLN, PRTA, YDES, CTMX, VALN. Left out: DRUG (period gap), AGMB (no annual filing), PRTC (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NGNE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NGNE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NGNE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.